

09743483

=> d his

(FILE 'HOME' ENTERED AT 16:42:57 ON 05 NOV 2002)

FILE 'REGISTRY' ENTERED AT 16:43:11 ON 05 NOV 2002

L1 STRUCTURE UPLOADED

L2 9 S L1

L3 322 S L1 SSS FULL


FILE 'CAPLUS' ENTERED AT 16:44:33 ON 05 NOV 2002

L4 25 S L3

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 C,N

G2 Cy,Ak

G3 [01], [02], [03]

Structure attributes must be viewed using STN Express query preparation.


=>

09 / 743,483


09743483

=> d 1-4 bib abs hitstr


L4 ANSWER 1 OF 25 CAPLUS COPYRIGHT 2002 ACS
AN 2002:429704 CAPLUS
DN 137:154885
TI Solution-Phase Parallel Synthesis of Substituted Benzimidazoles
AU Raju, B.; Nguyen, Noel; Holland, George W.
CS Department of Chemistry & Biophysics, Texas Biotechnology Corporation,
Houston, TX, 77030, USA
SO Journal of Combinatorial Chemistry (2002), 4(4), 320-328
CODEN: JCCHFF; ISSN: 1520-4766
PB American Chemical Society
DT Journal
LA English
GI



AB A procedure for soln.-phase parallel synthesis of benzimidazoles I and II (R1 = H, MeO2C; R2 = Me2CHCH2, PhCH2CH2, etc.; R3 = Bu, PhCOCH2, Me3CCO2CH2, etc.) with three points of diversity in excellent purities and yields via the corresponding o-phenylenediamines III was developed. High-throughput purifn. of this multistep synthetic sequence was accomplished using polymer-bound scavengers and reagents and liq.-liq. extn. protocols.
IT 246226-36-8P 445466-71-7P 445466-72-8P
445466-73-9P 445466-74-0P 445466-75-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(soln.-phase parallel synthesis of substituted mercaptobenzimidazoles)
RN 246226-36-8 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[[[4-(methoxycarbonyl)phenyl]methyl]thio]-1-(2-methylpropyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 445466-71-7 CAPLUS
CN Benzoic acid, 4-[[[1-(2-phenylethyl)-1H-benzimidazol-2-yl]thio]methyl]-, methyl ester (9CI) (CA INDEX NAME)



09743483


RN 445466-72-8 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[[[4-(methoxycarbonyl)phenyl]methyl]thio]-1-(3-methylbutyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 445466-73-9 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[[[4-(methoxycarbonyl)phenyl]methyl]thio]-1-[2-(2-thienyl)ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 445466-74-0 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[[[4-(methoxycarbonyl)phenyl]methyl]thio]-1-(2-phenylethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 445466-75-1 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 1-(3,3-diphenylpropyl)-2-[[[4-(methoxycarbonyl)phenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 25 CAPLUS COPYRIGHT 2002 ACS

AN 2001:545689 CAPLUS

DN 135:107332

TI Preparation of benzimidazole derivatives as clinically applicable human chymase inhibitors

IN Matsumoto, Yoshiyuki; Saitou, Hiroshi; Mizuno, Tsuyoshi

PA Teijin Ltd., Japan


SO PCT Int. Appl., 122 pp.

CODEN: PIXXD2


09743483

DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001053291	A1	20010726	WO 2001-JP271	20010117
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001027049	A5	20010731	AU 2001-27049	20010117
	EP 1249450	A1	20021016	EP 2001-901397	20010117
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI	JP 2000-7533	A	20000117		
	JP 2000-392303	A	20001225		
	WO 2001-JP271	W	20010117		
OS	MARPAT 135:107332				
GI					



I



II

AB Title compds. [I; R1, R2 independently = H, CH3, CH3O, alkyl, alkoxy; A = (CH2)3, (CH2)4, alkylene, alkenylene; E = COOR3, SO3R3, CONHR3, SO2NHR3; R3 = H, CH2CH3; G = CH2, CH2CH2, alkylene; M = single bond, S; J = heteroaryl; X = CH, N] and medically acceptable salts are prepd. as clin. applicable human chymase inhibitors. Thus, the title compd. II was prepd. and biol. tested.



IT 255397-53-6P 255397-54-7P 255397-55-8P
349668-38-8P 349668-39-9P 349668-41-3P
349668-42-4P 349668-51-5P 349668-52-6P
349668-53-7P 349668-54-8P 349668-55-9P
349668-64-0P 349668-65-1P 349668-66-2P
349668-67-3P 349668-73-1P 349668-74-2P
349668-75-3P 349668-76-4P 349668-77-5P
349668-78-6P 349668-79-7P 349668-81-1P
349668-82-2P 349668-83-3P 349668-84-4P
349668-86-6P 349668-87-7P 349668-88-8P
349668-89-9P 349668-90-2P 349668-91-3P
349668-93-5P 349668-94-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of benzimidazole derivs. as clin. applicable human chymase inhibitors)

RN 255397-53-6 CAPLUS



CN Butanoic acid, 4-[[1-(benzo[b]thien-3-ylmethyl)-5,6-dimethyl-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)

09743483




RN 255397-54-7 CAPLUS

CN Butanoic acid, 4-[[1-(benzo[b]thien-3-yl)methyl]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)




RN 255397-55-8 CAPLUS

CN Butanoic acid, 4-[[1-[(1-methyl-1H-indol-3-yl)methyl]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)




RN 349668-38-8 CAPLUS

CN Butanoic acid, 4-[[1-[(1,5-dimethyl-1H-indol-3-yl)methyl]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)



RN 349668-39-9 CAPLUS


CN Butanoic acid, 4-[[1-[(1,4-dimethyl-1H-indol-3-yl)methyl]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)



RN 349668-41-3 CAPLUS


09743483

CN Butanoic acid, 4-[[1-[(4-chloro-1-methyl-1H-indol-3-yl)methyl]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)





RN 349668-42-4 CAPLUS

CN Butanoic acid, 4-[[1-[(4-fluoro-1-methyl-1H-indol-3-yl)methyl]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)





RN 349668-51-5 CAPLUS

CN Butanoic acid, 4-[[1-[(5-chlorobenzo[b]thien-3-yl)methyl]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)



RN 349668-52-6 CAPLUS



CN Butanoic acid, 4-[[1-[(5-methylbenzo[b]thien-3-yl)methyl]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)





RN 349668-53-7 CAPLUS

CN Butanoic acid, 4-[[1-[(4-methylbenzo[b]thien-3-yl)methyl]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)


09743483




RN 349668-54-8 CAPLUS
CN Butanoic acid, 4-[[1-[(4-chlorobenzo[b]thien-3-yl)methyl]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)



RN 349668-55-9 CAPLUS
CN Butanoic acid, 4-[[1-[(4,6-dimethylbenzo[b]thien-3-yl)methyl]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)





RN 349668-64-0 CAPLUS
CN Butanoic acid, 4-[[1-[(1,4-dimethyl-1H-indol-3-yl)methyl]-1H-benzimidazol-2-yl]thio]-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 349668-65-1 CAPLUS
CN Butanoic acid, 4-[[1-(benzo[b]thien-3-ylmethyl)-1H-benzimidazol-2-yl]thio]-, sodium salt (9CI) (CA INDEX NAME)


09743483



● Na

RN 349668-66-2 CAPLUS



CN Butanoic acid, 4-[[1-[(1,4-dimethyl-1H-indol-3-yl)methyl]-5-methoxy-1H-benzimidazol-2-yl]thio]-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 349668-67-3 CAPLUS

CN Butanoic acid, 4-[[1-(benzo[b]thien-3-ylmethyl)-5,6-dimethyl-1H-benzimidazol-2-yl]thio]-, sodium salt (9CI) (CA INDEX NAME)





● Na

RN 349668-73-1 CAPLUS



CN Butanoic acid, 4-[[1-(benzo[b]thien-3-ylmethyl)-5,6-dimethyl-1H-benzimidazol-2-yl]thio]-, monohydrochloride (9CI) (CA INDEX NAME)

09743483




● HCl

RN 349668-74-2 CAPLUS
CN Butanoic acid, 4-[[1-[(5-methylbenzo[b]thien-3-yl)methyl]-1H-benzimidazol-2-yl]thio]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 349668-75-3 CAPLUS
CN Butanoic acid, 4-[[1-[(1,4-dimethyl-1H-indol-3-yl)methyl]-5-methoxy-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)





RN 349668-76-4 CAPLUS
CN Butanoic acid, 4-[[1-[(4-chloro-1-methyl-1H-indol-3-yl)methyl]-5-methoxy-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)





RN 349668-77-5 CAPLUS
CN Butanoic acid, 4-[[1-(benzo[b]thien-3-ylmethyl)-5-methoxy-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)

09743483





RN 349668-78-6 CAPLUS

CN Butanoic acid, 4-[[5-methoxy-1-[(5-methylbenzo[b]thien-3-yl)methyl]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)





RN 349668-79-7 CAPLUS

CN Butanoic acid, 4-[[5-methoxy-1-[(4-methylbenzo[b]thien-3-yl)methyl]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)



RN 349668-81-1 CAPLUS



CN Butanoic acid, 4-[[1-(benzo[b]thien-3-ylmethyl)-5-methyl-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)



RN 349668-82-2 CAPLUS


CN Butanoic acid, 4-[[1-(benzo[b]thien-3-ylmethyl)-6-methyl-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)

09743483




RN 349668-83-3 CAPLUS

CN Butanoic acid, 4-[[5,6-dimethyl-1-[(1-methyl-1H-indol-3-yl)methyl]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)




RN 349668-84-4 CAPLUS

CN Butanoic acid, 4-[[1-[(1,4-dimethyl-1H-indol-3-yl)methyl]-5,6-dimethyl-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)





RN 349668-86-6 CAPLUS

CN Butanoic acid, 4-[[1-[(4-chloro-1-methyl-1H-indol-3-yl)methyl]-5,6-dimethyl-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)





RN 349668-87-7 CAPLUS

CN Butanoic acid, 4-[[1-[(5-chlorobenzo[b]thien-3-yl)methyl]-5,6-dimethyl-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)





09743483





RN 349668-88-8 CAPLUS

CN Butanoic acid, 4-[[[5,6-dimethyl-1-[(5-methylbenzo[b]thien-3-yl)methyl]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)




RN 349668-89-9 CAPLUS

CN Butanoic acid, 4-[[[5,6-dimethyl-1-[(4-methylbenzo[b]thien-3-yl)methyl]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)



RN 349668-90-2 CAPLUS



CN Butanoic acid, 4-[[[5,6-dichloro-1-[(1,4-dimethyl-1H-indol-3-yl)methyl]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)



RN 349668-91-3 CAPLUS



CN Butanoic acid, 4-[[[1-(benzo[b]thien-3-ylmethyl)-5,6-dichloro-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)

09743483





RN 349668-93-5 CAPLUS

CN Butanoic acid, 4-[[6-methoxy-1-[(5-methylbenzo[b]thien-3-yl)methyl]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)



RN 349668-94-6 CAPLUS

CN Butanoic acid, 4-[[6-methoxy-1-[(4-methylbenzo[b]thien-3-yl)methyl]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)



IT 349668-34-4P 349668-59-3P 349668-62-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


```



```

RN 349668-34-4 CAPLUS



CN Butanoic acid, 4-[[1-[(1,4-dimethyl-1H-indol-3-yl)methyl]-1H-benzimidazol-2-yl]thio]-, ethyl ester (9CI) (CA INDEX NAME)



RN 349668-59-3 CAPLUS


CN Butanoic acid, 4-[[1-(benzo[b]thien-3-ylmethyl)-5-methoxy-1H-benzimidazol-2-yl]thio]-, ethyl ester (9CI) (CA INDEX NAME)

09743483



RN 349668-62-8 CAPLUS

CN Butanoic acid, 4-[[1-[(1-methyl-1H-indol-3-yl)methyl]-1H-benzimidazol-2-yl]thio]-, ethyl ester (9CI) (CA INDEX NAME)





IT 349668-70-8P

RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
USES (Uses)
(prepn. of benzimidazole derivs. as clin. applicable human chymase
inhibitors)

RN 349668-70-8 CAPLUS

CN Butanoic acid, 4-[[5-methoxy-1-[(4-methylbenzo[b]thien-3-yl)methyl]-1H-benzimidazol-2-yl]thio]-, ethyl ester (9CI) (CA INDEX NAME)




IT 349668-35-5P 349668-36-6P 349668-37-7P
349668-40-2P 349668-43-5P 349668-44-6P
349668-45-7P 349668-46-8P 349668-47-9P
349668-48-0P 349668-49-1P 349668-50-4P
349668-68-4P 349668-71-9P 349668-72-0P
349668-85-5P 349668-95-7P 349668-96-8P
349668-97-9P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
study); PREP (Preparation); USES (Uses)
(prepn. of benzimidazole derivs. as clin. applicable human chymase
inhibitors)

RN 349668-35-5 CAPLUS


CN Butanoic acid, 4-[[1-[(1,2-dimethyl-1H-indol-3-yl)methyl]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)

09743483




RN 349668-36-6 CAPLUS

CN Butanoic acid, 4-[[1-[(1,7-dimethyl-1H-indol-3-yl)methyl]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)




RN 349668-37-7 CAPLUS

CN Butanoic acid, 4-[[1-[(1,6-dimethyl-1H-indol-3-yl)methyl]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)




RN 349668-40-2 CAPLUS

CN Butanoic acid, 4-[[1-[(1,2,5-trimethyl-1H-indol-3-yl)methyl]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)



RN 349668-43-5 CAPLUS


CN Butanoic acid, 4-[[1-[(4-methoxy-1-methyl-1H-indol-3-yl)methyl]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)



RN 349668-44-6 CAPLUS


CN Butanoic acid, 4-[[1-[(1-methyl-2-phenyl-1H-indol-3-yl)methyl]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)

09743483




RN 349668-45-7 CAPLUS

CN Butanoic acid, 4-[[1-[(1,2-diphenyl-1H-indol-3-yl)methyl]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)




RN 349668-46-8 CAPLUS

CN Butanoic acid, 4-[[1-[(5-chloro-1-methyl-1H-indol-3-yl)methyl]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)




RN 349668-47-9 CAPLUS

CN Butanoic acid, 4-[[1-[(5-fluoro-1-methyl-1H-indol-3-yl)methyl]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)



RN 349668-48-0 CAPLUS


CN Butanoic acid, 4-[[1-[(5-methoxy-1-methyl-1H-indol-3-yl)methyl]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)



RN 349668-49-1 CAPLUS


CN Butanoic acid, 4-[[1-[(5-cyano-1-methyl-1H-indol-3-yl)methyl]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)

09743483





RN 349668-50-4 CAPLUS

CN Butanoic acid, 4-[[1-[(6-methoxy-1-methyl-1H-indol-3-yl)methyl]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)





RN 349668-68-4 CAPLUS

CN Butanoic acid, 4-[[6-methoxy-1-[(4-methylbenzo[b]thien-3-yl)methyl]-1H-benzimidazol-2-yl]thio]-, ethyl ester (9CI) (CA INDEX NAME)



RN 349668-71-9 CAPLUS



CN Butanoic acid, 4-[[5-methoxy-1-[(5-methylbenzo[b]thien-3-yl)methyl]-1H-benzimidazol-2-yl]thio]-, ethyl ester (9CI) (CA INDEX NAME)



RN 349668-72-0 CAPLUS


CN Butanoic acid, 4-[[6-methoxy-1-[(5-methylbenzo[b]thien-3-yl)methyl]-1H-benzimidazol-2-yl]thio]-, ethyl ester (9CI) (CA INDEX NAME)

09743483



RN 349668-85-5 CAPLUS



CN Butanoic acid, 4-[[1-[(1,4-dimethyl-1H-indol-3-yl)methyl]-5,6-dimethyl-1H-benzimidazol-2-yl]thio]-, sodium salt (9CI) (CA INDEX NAME)



● Na


RN 349668-95-7 CAPLUS

CN Butanoic acid, 4-[[1-[2-(1-methyl-1H-indol-3-yl)ethyl]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)



RN 349668-96-8 CAPLUS


CN Butanoic acid, 4-[[1-[(7-chloro-4-methylbenzo[b]thien-3-yl)methyl]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)



RN 349668-97-9 CAPLUS

CN Butanoic acid, 4-[[1-[(7-bromo-4-methylbenzo[b]thien-3-yl)methyl]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)

09743483




RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 25 CAPLUS COPYRIGHT 2002 ACS
AN 2001:545672 CAPLUS
DN 135:132433
TI Benzimidazole derivatives as human chymase inhibitors
IN Tsuchiya, Naoki; Matsumoto, Yoshiyuki; Saitou, Hiroshi; Mizuno, Tsuyoshi
PA Teijin Ltd., Japan
SO PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001053272	A1	20010726	WO 2001-JP272	20010117
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1167360	A1	20020102	EP 2001-901398	20010117
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI JP 2000-7532	A	20000117		
JP 2000-10406	A	20000119		
WO 2001-JP272	W	20010117		

GI



I


AB Benzimidazole derivs. of the general formula (I) or medically acceptable salts thereof, and human chymase inhibitors contg. the derivs. or the salts as the active ingredient: wherein ring A is a pyridine ring or a benzene ring; X1 and X2 are each hydrogen, halogeno, trihalomethyl, cyano, optionally substituted alkyl, optionally substituted alkoxy, or the like; B is optionally substituted alkylene or the like; E is COOR₄ or the like; G is optionally substituted alkylene; J is optionally substituted alkyl or optionally substituted aryl; and M is sulfur, sulfinyl, sulfonyl, or the like.

IT 255397-98-9P 351520-26-8P 351520-28-0P
351520-32-6P 351520-37-1P 351520-39-3P
351520-41-7P 351520-42-8P 351520-44-0P
351520-45-1P 351520-47-3P 351520-48-4P
351520-50-8P 351520-51-9P 351520-52-0P
351520-53-1P 351520-54-2P 351520-55-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(benzimidazole derivs. as human chymase inhibitors for treatment of related diseases)

09743483


RN 255397-98-9 CAPLUS

CN Butanoic acid, 4-[[5,6-dimethyl-1-(1-naphthalenylmethyl)-1H-benzimidazol-2-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 351520-26-8 CAPLUS

CN Butanoic acid, 4-[[5-methoxy-1-(1-naphthalenylmethyl)-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)




RN 351520-28-0 CAPLUS

CN Butanoic acid, 4-[[5,6-difluoro-1-(1-naphthalenylmethyl)-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)



RN 351520-32-6 CAPLUS


CN Butanoic acid, 4-[[5-mercapto-1-(1-naphthalenylmethyl)-1H-benzimidazol-2-yl]thio]-, ethyl ester (9CI) (CA INDEX NAME)




RN 351520-37-1 CAPLUS

CN Butanoic acid, 4-[[5-cyano-1-(1-naphthalenylmethyl)-1H-benzimidazol-2-yl]thio]-3,3-dimethyl- (9CI) (CA INDEX NAME)


09743483



RN 351520-39-3 CAPLUS
CN Butanoic acid, 4-[[1-(1-naphthalenylmethyl)-1H-benzimidazol-2-yl]thio]-
(9CI) (CA INDEX NAME)




RN 351520-41-7 CAPLUS
CN Butanoic acid, 4-[[1-(1-naphthalenylmethyl)-1H-benzimidazol-2-yl]thio]-,
sodium salt (9CI) (CA INDEX NAME)




● Na

RN 351520-42-8 CAPLUS
CN Butanoic acid, 4-[[1-[(8-methyl-1-naphthalenyl)methyl]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)




RN 351520-44-0 CAPLUS
CN Butanoic acid, 4-[[5,6-dimethyl-1-[(8-methyl-1-naphthalenyl)methyl]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)

09743483




RN 351520-45-1 CAPLUS

CN Pentanoic acid, 3,3-dimethyl-5-[[1-(1-naphthalenylmethyl)-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)




RN 351520-47-3 CAPLUS

CN Butanoic acid, 4-[[1-(1-naphthalenylmethyl)-5-(trifluoromethyl)-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)




RN 351520-48-4 CAPLUS

CN Butanoic acid, 4-[[1-[(2,5-dimethylphenyl)methyl]-5-methoxy-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)




RN 351520-50-8 CAPLUS


CN Butanoic acid, 4-[[5-cyano-1-[(2,5-dimethylphenyl)methyl]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)




09743483




RN 351520-51-9 CAPLUS
CN Butanoic acid, 4-[[5-ethoxy-1-(1-naphthalenylmethyl)-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)




RN 351520-52-0 CAPLUS
CN Propanoic acid, 3-[[1-(1-naphthalenylmethyl)-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)



RN 351520-53-1 CAPLUS
CN Pentanoic acid, 5-[[1-(1-naphthalenylmethyl)-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)




RN 351520-54-2 CAPLUS
CN Butanoic acid, 4-[[5,6-dimethyl-1-(1-naphthalenylmethyl)-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)



09743483

RN 351520-55-3 CAPLUS

CN Butanoic acid, 4-[[3-[(2,5-dimethylphenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]thio]- (9CI) (CA INDEX NAME)



IT 351520-31-5P 351520-36-0P 351520-38-2P


351520-40-6P 351520-43-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(benzimidazole derivs. as human chymase inhibitors for treatment of related diseases)


RN 351520-31-5 CAPLUS

CN Butanoic acid, 4-[[5,6-difluoro-1-(1-naphthalenylmethyl)-1H-benzimidazol-2-yl]thio]-, ethyl ester (9CI) (CA INDEX NAME)




RN 351520-36-0 CAPLUS

CN Butanoic acid, 4-[[5-cyano-1-(1-naphthalenylmethyl)-1H-benzimidazol-2-yl]thio]-, ethyl ester (9CI) (CA INDEX NAME)



RN 351520-38-2 CAPLUS


CN Butanoic acid, 4-[[5-cyano-1-(1-naphthalenylmethyl)-1H-benzimidazol-2-yl]thio]-3,3-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



09743483


RN 351520-40-6 CAPLUS

CN Butanoic acid, 4-[[1-(1-naphthalenylmethyl)-1H-benzimidazol-2-yl]thio]-, ethyl ester (9CI) (CA INDEX NAME)



RN 351520-43-9 CAPLUS

CN Butanoic acid, 4-[[1-[(8-methyl-1-naphthalenyl)methyl]-1H-benzimidazol-2-yl]thio]-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 25 CAPLUS COPYRIGHT 2002 ACS

AN 2000:792791 CAPLUS

DN 137:201256

TI Combinatorially liquid-phase synthesis of structurally diverse benzimidazole libraries. [Erratum to document cited in CA133:17422]

AU Yeh, Chih-Ming; Tung, Chieh-Li; Sun, Chung-Ming

CS Taiwan

SO Journal of Combinatorial Chemistry (2001), 3(2), 229

CODEN: JCCHFF; ISSN: 1520-4766

PB American Chemical Society

DT Journal

LA English

AB On page 342, the structure of thiophosgene in Scheme 1 is incorrect; the cor. scheme is given.

IT 246226-36-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(combinatorial liq.-phase synthesis of benzimidazole libraries
(Erratum))

RN 246226-36-8 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[[[4-(methoxycarbonyl)phenyl]methyl]thio]-1-(2-methylpropyl)-, methyl ester (9CI) (CA INDEX NAME)

